Original: $122.53
-65%$122.53
$42.89The Story
erendia is a non-steroidal mineralocorticoid receptor
antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end
stage kidney disease, cardiovascular death, non-fatal myocardial infarction,
and hospitalization for heart failure in adult patients with chronic kidney
disease (CKD) associated with type 2 diabetes (T2D)
erendia is a non-steroidal mineralocorticoid receptor
antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end
stage kidney disease, cardiovascular death, non-fatal myocardial infarction,
and hospitalization for heart failure in adult patients with chronic kidney
disease (CKD) associated with type 2 diabetes (T2D)
indicated to reduce the risk of sustained eGFR decline, end stage kidney
disease, cardiovascular death, non-fatal myocardial infarction, and
hospitalization for heart failure in adult patients with chronic kidney disease
(CKD) associated with type 2 diabetes (T2D)
Details & Craftsmanship
Every detail has been carefully considered to bring you the perfect product.
Description
erendia is a non-steroidal mineralocorticoid receptor
antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end
stage kidney disease, cardiovascular death, non-fatal myocardial infarction,
and hospitalization for heart failure in adult patients with chronic kidney
disease (CKD) associated with type 2 diabetes (T2D)
erendia is a non-steroidal mineralocorticoid receptor
antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end
stage kidney disease, cardiovascular death, non-fatal myocardial infarction,
and hospitalization for heart failure in adult patients with chronic kidney
disease (CKD) associated with type 2 diabetes (T2D)
indicated to reduce the risk of sustained eGFR decline, end stage kidney
disease, cardiovascular death, non-fatal myocardial infarction, and
hospitalization for heart failure in adult patients with chronic kidney disease
(CKD) associated with type 2 diabetes (T2D)
